Onaiza Cadoret Manier

Onaiza Cadoret Manier is an international commercialization and operations executive with 25 years driving growth for Fortune 500 and start-up companies—Genentech, Pfizer, and Amylin Pharmaceuticals. She is recognized for strategic and inspirational leadership, launching new products, and reviving landmark brands across multiple therapeutic areas.

Onaiza has been at Genentech since 2011 leading and building the respiratory commercial team at Genentech. First with Omalizumab (Xolair), where she was responsible for the allergic asthma business and the launch into chronic idiopathic urticaria, followed by an extension of Xolair to pediatric population ages 6 and older. In 2014, Onaiza leads the commercial launch Pirfendidone (Esbriet) for idiopathic pulmonary fibrosis. She was a key contributor to the due diligence team that supported the acquisition of Intermune, and the United States Food and Drug Administration (FDA) label discussions for Esbriet. As the commercial lead for Esbriet in the U.S., she integrated and led a highly successful U.S. launch of Esbriet for idiopathic pulmonary fibrosis patients. She currently works across all three in-line products, Xolair®, Esbriet®, and Pulmozyme ®, and with lifecycle teams to advance the science for unmet needs in respiratory patient care.